Skip to content
AnalystLens

CENTENE CORP 8-K Report, Regulation FD Disclosure (Mar 10, 2026)

Reports
Regulation FD·Other Events
Filing Date
Filed March 10, 2026
Period End
March 10, 2026
Security
CNC
In the record · 2016–202610-K1110-Q328-K217

CNC filed 11 annual reports (10-K), 32 quarterly reports (10-Q) and 217 current reports (8-K) between 2016 and 2026.

  1. Deal closed8-K · Jul ’18Jul ’18
  2. Leadership change8-K · Dec ’20Dec ’20
  3. Leadership change8-K · Dec ’22Dec ’22
  4. Material agreement8-K · Mar ’25Mar ’25

01—Abstract

Summary

Summary of the 8-K filed March 10, 2026. Cited figures are marked; the original filing is the authoritative source.

Centene Corporation has filed an 8-K report on March 10, 2026, primarily to provide an update ahead of their presentation at the Barclays 28th Annual Global Healthcare Conference.

The key takeaway for investors is the reaffirmation of the company's previously issued 2026 full-year financial guidance. Centene expects to achieve GAAP diluted earnings per share (EPS) greater than $1.98a and adjusted diluted EPS greater than $3.00, signaling confidence in their operational performance and outlook for the remainder of the fiscal year. In addition to reaffirming guidance, the report disclosed Centene's intention to partially redeem its outstanding 4.25% Notes due December 15, 2027.

The company plans to redeem $1,000,000,000b in aggregate principal amount of these notes on March 25, 2026, with approximately $1,186,664,000 of the notes remaining outstanding. This action suggests a proactive approach to managing its debt obligations and capital structure.

02—Key points

Key Highlights

  1. Centene Corporation reaffirms its 2026 full-year GAAP diluted EPS guidance of greater than $1.98.
  2. Centene Corporation reaffirms its 2026 full-year adjusted diluted EPS guidance of greater than $3.00.
  3. The company will present at the Barclays 28th Annual Global Healthcare Conference on March 10, 2026.
  4. Centene plans to redeem $1,000,000,000 in aggregate principal amount of its 4.25% Notes due December 15, 2027.
  5. The partial redemption of the 2027 Notes is scheduled for March 25, 2026.
  6. Approximately $1,186,664,000 of the 2027 Notes will remain outstanding after the redemption.
  7. The company utilizes non-GAAP financial measures to provide a more consistent view of ongoing operations and performance.

03—Questions

Frequently Asked Questions

  1. What is the key financial guidance Centene reaffirmed for 2026?

    Centene reaffirmed its previously issued 2026 full-year GAAP diluted EPS guidance of greater than $1.98 and its full-year adjusted diluted EPS guidance of greater than $3.00.

  2. What debt action did Centene announce?

    Centene announced its intention to partially redeem $1,000,000,000 aggregate principal amount of its outstanding 4.25% Notes due December 15, 2027. This redemption is set to occur on March 25, 2026.

  3. Where can investors find more information about Centene's presentation?

    Investors can access a live audio webcast of the presentation from the Barclays 28th Annual Global Healthcare Conference on March 10, 2026, via the company's website at www.centene.com, in the Investors section. A webcast replay will also be available following the presentation.

  4. What is the purpose of Centene's use of non-GAAP financial measures?

    Centene uses non-GAAP financial measures, such as adjusted diluted EPS, to help investors more accurately assess the ongoing nature of its operations and measure performance more consistently across periods. These measures often exclude items like amortization of acquired intangible assets and acquisition/divestiture related expenses to provide a clearer view of core business performance.

04—Continue

← View all 8-K filings